Iclusig is a medicine used to treat certain types of leukemia, a cancer of the blood. It is taken as a pill by mouth. It works by blocking a faulty protein that tells the cancer cells to grow.
Every report comes from a Lived member, sent anonymously.
Have you tried Iclusig (Ponatinib) for CML (Chronic Myeloid Leukemia)?
Ponatinib, sold as Iclusig, is a prescription cancer pill for adults with two blood cancers driven by the Philadelphia chromosome: chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The Philadelphia chromosome is a swap of genetic material between two chromosomes in leukemia cells. It creates an abnormal gene, BCR::ABL1, that keeps those cells multiplying. In CML, ponatinib is mainly used after other options. It is approved for chronic phase CML when at least two earlier kinase inhibitors (the targeted pills usually used first) have stopped working or could not be tolerated, and for the more advanced accelerated and blast phases when no other kinase inhibitor is suitable. It is not recommended for newly diagnosed chronic phase CML. In Ph+ ALL, it is approved together with chemotherapy for newly diagnosed adults, and on its own when other kinase inhibitors are not suitable. The approval with chemotherapy is an accelerated one: it rests on more people reaching a deep early remission, and a further trial is confirming the longer-term benefit. Ponatinib is also an option for either leukemia when the cancer carries a change called T315I, a mutation that makes the leukemia resistant to most other drugs in this family.
The abnormal BCR::ABL1 gene produces a protein, a tyrosine kinase, that acts like a switch stuck in the on position, constantly telling leukemia cells to grow. Kinase inhibitors block that switch. Ponatinib was designed so it still fits the protein when the T315I mutation has changed its shape, which is why it can work after other kinase inhibitors have failed. Ponatinib also blocks several other kinases, including ones involved in blood vessel growth and repair. That broader reach is thought to contribute to its effects on blood vessels and blood pressure, which shape how carefully it is dosed and monitored.
Ponatinib is a tablet taken by mouth once a day, with or without food. The starting dose depends on the diagnosis: people with newly diagnosed Ph+ ALL start at a lower dose alongside chemotherapy, while most other uses start higher. In chronic phase CML, the dose is usually lowered once blood tests show the leukemia has dropped to a low level, because a lower dose helps keep the response while reducing the risk to blood vessels. Swallow the tablets whole; do not crush, cut or chew them. If a dose is missed, skip it and take the next dose at the usual time the next day rather than doubling up. Doses are often paused or reduced to manage side effects, so changes should come only from the treating team.
Common side effects include rash, dry skin, joint pain, headache, tiredness, constipation, nausea and abdominal pain. Blood pressure often rises, and blood tests may show lower platelet and white cell counts or changes in liver and pancreas tests. When ponatinib is given with chemotherapy, mouth sores and fever with low white cells are also common. Chest pain, sudden weakness or numbness on one side of the body, or trouble speaking can signal a heart attack or stroke and need a 911 call right away. Contact the care team immediately for leg pain or swelling, new or worsening shortness of breath, a racing or irregular heartbeat, fainting, yellowing of the skin or eyes, unusual bleeding or bruising, a fever, or abdominal pain with nausea or vomiting. Report vision changes and numbness, tingling or burning in the hands or feet promptly as well.
Ponatinib carries an FDA boxed warning, the agency's most serious, for blood vessel and organ harm. It can cause heart attacks, strokes, severe narrowing of arteries and blood clots in veins, including fatal events. These have happened in people with and without heart risk factors, including people 50 or younger, sometimes within weeks of starting and at lower doses. It can also cause heart failure and serious liver damage, including liver failure. Because of these risks, the care team weighs the expected benefit against each person's heart and vascular health before starting and while continuing. Some medicines change ponatinib levels in the blood. Strong blockers of CYP3A, the liver enzyme that breaks it down (such as the antifungal ketoconazole), can raise levels and side effects, while strong inducers (such as the seizure medicine carbamazepine or the antibiotic rifampin) can lower them and weaken treatment. Avoid grapefruit and grapefruit juice, which also raise levels. Share a full list of medicines and supplements with the oncology team and pharmacist. Ponatinib can harm a developing baby. Women who could become pregnant should use effective contraception during treatment and for 3 weeks after the last dose, and should not breastfeed during treatment or for 1 week after. It may also reduce female fertility. Because it can slow wound healing, it is usually stopped at least a week before planned surgery, so tell the team about any upcoming procedure.
Treatment comes with regular monitoring. Blood counts are checked every 2 weeks for the first 3 months and then about monthly. Blood pressure, liver tests and lipase (a pancreas enzyme) are checked throughout, and an eye exam is done at the start and periodically. Before starting, the team usually reviews heart health, blood pressure, cholesterol and blood sugar, since controlling these may lower vascular risk. Response is tracked with a blood test that measures how much BCR::ABL1 remains. If the leukemia has not responded within about 3 months, the team may consider stopping. In CML, people who respond often continue long term at a reduced dose. In newly diagnosed Ph+ ALL, ponatinib is given alongside chemotherapy cycles as part of a planned course. Many people have at least one pause or dose change along the way to manage side effects. Staying in close contact with the oncology team, and keeping lab and blood pressure appointments, is a central part of using this medicine safely.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Iclusig (Ponatinib), what you've noticed, or ask the community a question.